Search
New York Paid Clinical Trials
A listing of 4503 clinical trials in New York actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2233 - 2244 of 4503
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Ischemic heart disease (IHD) Clinical Study
Recruiting
A clinical study for people that suffer with Ischemic heart disease (IHD)
Conditions:
Ischemic heart disease (IHD)
Collection of Samples USOPTIVAL Study
Recruiting
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Gender:
ALL
Ages:
Between 45 years and 84 years
Trial Updated:
06/04/2025
Locations: Mid Hudson Medical Research, New Windsor, New York
Conditions: Colorectal Cancer (CRC), Advanced Adenomas (AA)
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Recruiting
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Columbia University Irving Medical Center, New York City, New York
Conditions: Monoclonal Gammopathy
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Recruiting
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York
Conditions: Metastatic Non-small Cell Lung Cancer
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Recruiting
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogen... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/04/2025
Locations: University of Rochester, Rochester, New York
Conditions: Myotonic Dystrophy 1, DM1
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Recruiting
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: NYU Langone Medical Center, New York, New York
Conditions: Melanoma
Bridging the Evidence-to-practice Gap
Recruiting
The proposed project will address this evidence-to-practice gap by evaluating the effect of practice facilitation (PF) of the intervention implementation fidelity (primary outcome) and clinical measures at 12 months (secondary outcomes).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/04/2025
Locations: NYUMC Langone, New York, New York
Conditions: Hypertension
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls, New York
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
Recruiting
The purpose of this study is to find the smallest amount of the 131 I-apamistamab needed for preparing patients with severe sickle cell disease (SCD) for a bone marrow transplant. This is the first time 131 I-apamistamab is being used for advanced Sickle Cell Disease (SCD) in the setting of allogeneic stem cell transplant. 131 I-apamistamab is an investigational product. This means that 131 I-apamistamab has not been approved by the Food and Drug Administration (FDA) for medical use in patients.... Read More
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/03/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Sickling Disorder Due to Hemoglobin S
Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS
Recruiting
The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are:
Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve fu... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/03/2025
Locations: Stony Brook University, Stony Brook, New York
Conditions: Chronic Fatigue Syndrome
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Montefiore Cancer Center, New york, New York
Conditions: Solid Tumors
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
Recruiting
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospi... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/03/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
2233 - 2244 of 4503
When investigators decide to start a clinical trial, regulatory agencies such as the FDA and the IRB must review all plans and protocols to determine if the proposed trial is safe, ethical, and feasible. All clinical trials that recruit human participants have been reviewed and approved, and both non-paid and paid clinical research studies exist in New York.
After the study is approved the research team sets out to recruit volunteers who would like to participate in a clinical trial. Usually, volunteers are compensated for their time and travel expenses, and many paid clinical trials exist.
While one of the purposes of conducting clinical trials is testing the intervention on a large sample that would be representative of the general population, studies often have inclusion and exclusion criteria that outline who can and cannot participate. The inclusion criteria specifies the characteristics a participant must have in order to participate; for example, a liver cancer trial may have as an inclusion criteria that the participant must be a liver cancer patient.
On the other hand, the exclusion criteria outlines what type of individuals cannot participate; for example, a clinical trial testing a vitamin supplement in healthy individuals might want to disqualify participants who suffer from a serious condition and that can jeopardize the participant's ability to safely receive the experimental intervention. Due to safety concerns, pregnancy is often an exclusion criteria found in many studies.
In New York State, Columbia University and Mount Sinai Hospital are two of the largest research centers conducting clinical trials on a regular basis. As of this month, Columbia University is actively recruiting participants on at least 200 clinical trials from all phases, and Mount Sinai has over 500 active clinical trials.
Search Clinical Trials in New York by Condition
See All Conditions